Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity. ##STR00001##

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity. ##STR00001##

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1):

##STR00001##

wherein each of R.sup.1 and R.sup.2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R.sup.3a and R.sup.3b or R.sup.4a and R.sup.4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R.sup.5 (R.sup.5 represents, for example, a hydrogen atom or a C.sub.1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O).sub.l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.

An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1):

##STR00001##

wherein each of R.sup.1 and R.sup.2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R.sup.3a, R.sup.3b, R.sup.4a, and R.sup.4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R.sup.3a and R.sup.3b or R.sup.4a and R.sup.4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R.sup.5 (R.sup.5 represents, for example, a hydrogen atom or a C.sub.1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O).sub.l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.

The present invention provides compounds of formula I

##STR00001##

wherein X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.1a, R.sup.1b, R.sup.2′, R.sup.2″, R.sup.3′, R.sup.3″, R.sup.6 and R.sup.7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

The present invention provides compounds of formula I

##STR00001##

wherein X.sup.1, X.sup.2, X.sup.3, X.sup.4, R.sup.1, R.sup.1a, R.sup.1b, R.sup.2′, R.sup.2″, R.sup.3′, R.sup.3″, R.sup.6 and R.sup.7 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.

The present disclosure relates to compounds of Formula I: ##STR00001##
that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.

The present disclosure relates to compounds of Formula I: ##STR00001##
that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.